title: Reconstruction with non-vascularised fibular grafts after resection of bone tumours.
abstract: We evaluated 31 patients who were treated with a non-vascularised fibular graft after resection of primary musculoskeletal tumours, with a median follow-up of 5.6 years (3 to 26.7 years). Primary union was achieved in 89% (41 of 46) of the grafts in a median period of 24 weeks. All 25 grafts in 18 patients without additional chemotherapy and/or radiotherapy achieved primary union, compared with 16 of the 21 grafts (76%; 13 patients) with additional therapy (p=0.017). Radiographs showed an increase in diameter in 70% (59) of the grafts. There were seven fatigue fractures in six patients, but only two needed treatment. Non-vascularised fibular transfer is a simpler, less expensive and a shorter procedure than the use of vascularised grafts and allows remodelling of the fibula at the donor site. It is a biological reconstruction with good long-term results, and a relatively low donor site complication rate of 16%.
authors.affiliation: 1Orthopaedic Department Children's Hospital, University of Basel (UKBB), P O Box 4005, Basel, Switzerland. andreas.krieg@ukbb.ch
authors.forename: A H
authors.initials: AH
authors.lastname: Krieg
authors.forename: F
authors.initials: F
authors.lastname: Hefti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery* / Q000628:therapy; D016723:Bone Remodeling; D016025:Bone Transplantation / Q000009:adverse effects / Q000379:methods; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002648:Child; D002813:Chondrosarcoma / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy; D005260:Female; D005360:Fibula / Q000098:blood supply / Q000637:transplantation*; D005500:Follow-Up Studies; D015775:Fractures, Stress / Q000209:etiology; D006801:Humans; D015576:Hyperostosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000601:surgery / Q000628:therapy; D011859:Radiography; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D020127:Recovery of Function; D012039:Regional Blood Flow; D012512:Sarcoma, Ewing / Q000601:surgery / Q000628:therapy; D016896:Treatment Outcome